Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton May 10, 2024 11:27am
198 Views
Post# 36033643

RE:RE:Curious as to how the trial changes affect posted results !

RE:RE:Curious as to how the trial changes affect posted results !Yes, it would be great to start seeing some 2 year data. As of the 29 Aug 23 MD&A, 39 patients had reached the 15 month point. By the end of this month those 39 patients will have reached 24 months.

As of 29 Aug 23, 13 patients out of 39 (or 33%) were CR at 15 months. If the 24 month data of all 39 were made available it would be very instructive how many of those 13 patients are still CR.

Donein25 wrote: I think there will have to be new data sets because there will be new subsets of patients. Also, I think (due to BTD/AA requirements) that we might start to see 2 year data soon. I personally would be encouraged to see 2 year data come out...as it would say to me that we are complying with current FDA reporting requirements. 


<< Previous
Bullboard Posts
Next >>